The Corteva, Novartis, AbbVie and Heritage Medical Systems-backed cancer therapy developer priced a $304m initial public offering at the top of its range.

Baidu Ventures and AliHealth both invested in a series C round for the genome sequencing technology provider, which counts BGI as an existing investor.

Unilever Ventures and Sistema Asia Capital have backed the health and fitness app developer’s latest round, which took its overall funding past $100m.

Several corporates backed a $68m series D round for microbiome drug developer Vedanta Biosciences while grooming brand owner Pangaea raised the same amount from investors including Unilever.

TMRW Life Sciences is eyeing a global expansion of its frozen egg and embryo management services with new capital from investors including GV.

Danaher is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.

Nan Fung and Lam Research are set to exit the DNA sequencing technology developer in an $800m acquisition by market peer Pacific Biosciences.

Panakès Partners is now targeting a final close upwards of $210m for its Purple Fund, which has reached its Menarini-backed first close.

6 Dimensions Capital-backed neuromodulation technology developer Neuspera closed a $65m round while gene therapy developer Coave Therapeutics hiked its latest round to $39m.

Access Biotechnology is in line for an exit after the neuronal excitability disorder drug developer filed to float on the Nasdaq Global Market.